Page last updated: 2024-08-26

4-hydroxydebrisoquin and 10-hydroxynortriptyline

4-hydroxydebrisoquin has been researched along with 10-hydroxynortriptyline in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J	1

Trials

1 trial(s) available for 4-hydroxydebrisoquin and 10-hydroxynortriptyline

Article	Year
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia	2001

Article

Year

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4

Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia

2001